Effectiveness of SGLT2 Inhibitors in Improving Functional Capacity and Reducing Hospitalizations in Heart Failure...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently emerged as a promising therapeutic option for patients with heart failure with preserved ejection fraction (HFpEF), a condition historically resistant to pharmacological interventions. This systematic review synthesizes evidence from 10 randomized controlled trials evaluating the effects of empagliflozin and dapagliflozin on functional capacity and hospitalization outcomes in HFpEF patients. The findings consistently demonstrate significant improvements in patient-reported outcomes, such as the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores and six-minute walk test (6MWT) performance, along with reductions in heart failure hospitalizations. These benefits were observed across diverse patient populations, including older adults and those with comorbidities like diabetes and chronic obstructive pulmonary disease, with a favorable safety profile. The review supports the incorporation of SGLT2 inhibitors as a central component in the management of HFpEF, offering both symptomatic relief and a reduction in clinical events.